INDIANAPOLIS, March 3, 2016 /PRNewswire/ -- Roche Diabetes Care today announced the integration of the Accu-Chek Connect System with the Apple Health app on iPhone. The integration will allow patients using the Accu-Chek Connect app to share data with HealthKit and easily view their blood glucose levels and carbohydrates in the Health app alongside other activity and health information.
Experience the interactive Multimedia News Release here: http://www.multivu.com/players/English/7571631-roche-accu-chek-connect-diabetes/
The Accu-Chek Connect system is a diabetes management system that consists of the Accu-Chek Aviva Connect meter, an app (accu-chek.com/connect-ios), and an online portal that allows patients, caregivers, and healthcare providers to view, share, and access blood glucose data anytime, anywhere. In addition, a doctor can activate an insulin dosage calculator on the app, the Accu-Chek Bolus Advisor, which makes it easy to calculate how much insulin is needed at each meal. The simple-to-use meter wirelessly sends blood glucose results to the Accu-Chek Connect app on iPhone.
"For people with diabetes, simplifying the management of their condition can be an essential part of championing their own health and wellness. We are excited to announce the integration of Accu-Chek Connect with the Apple Health app," said Marc Gibeley, Head of Roche Diabetes Care North America. "This integration is the next step in helping those with diabetes adopt a holistic approach in managing their overall care, by allowing them to log, view, and share their diabetes data with other health tracking applications on their iPhone. It also provides healthcare teams with a better view of the patient's lifestyle as they assess the role of health and fitness in their management routine."
With user permission, other mobile apps such as electronic medical records apps or apps tracking health and wellness that integrate with HealthKit may also access this data. For example, with the help of HealthKit, blood glucose data will now be able to flow seamlessly from the Accu-Chek Aviva Connect meter to the Epic and Cerner EMR software.
To learn more about Accu-Chek blood glucose meters, infusion insulin pumps, lancing and data management systems, visit www.accu-chek.com. Accu-Chek Aviva Connect is available exclusively at Walgreens.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives.
Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For 40 years, the Accu-Chek brand has been dedicated to enable people with diabetes to live life as normal and active as possible as well as to empower healthcare professionals manage their patients' condition in an optimal way. Today, the Accu-Chek portfolio offers people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management. It encompasses blood glucose meters, insulin delivery systems, lancing devices, data management systems and education programs – contributing to an improved medical outcome. For more information: www.accu-chek.com.
All trademarks used or mentioned in this release are legally protected.
For more information please contact:
Head of Communications, Diabetes Care North America
l Ziegler R, Cavan DA, Cranston I, et al. Use of an insulin bolus advisor improves glycemic control in multiple daily insulin injection (MDI) therapy patients with suboptimal glycemic control: first results from the ABACUS trial. Diabetes Care. 2013;36:3613-3619.
SOURCE Roche Diabetes Care